Alan Rigby PhD

Alan Rigby is an experienced, oncology-focused, biotech founder, entrepreneur, and innovative leader focused on company ideation and strategic growth through capital raises, non-dilutive collaborative partnerships, and value-enhancing asset acquisitions. A mission-driven, patient-centric leader with an unwavering commitment to build, focus, and accelerate the advancement of innovative first-in-human, first-in-class therapies that impact patients’ lives.

As an oncology innovator, Alan co-founded and served as President and CEO of HiberCell, a company focused on leveraging multi-omic data to target the stress response pathways of dormant disseminated tumor cells with a goal of preventing cancer relapse.

Under his leadership, HiberCell launched in 2019 with a $61 million USD Series A and ultimately raised more than $250M USD. Before co-founding HiberCell, Alan held C-suite executive roles at Warp Drive Bio, Inc., Synta Pharmaceuticals, and was a Vice President of Oncology at Eli Lilly and Company, where he advanced several drug discovery and development programs. Before his career in biopharma and biotechnology, Alan served as an Assistant Professor and Adjunct Assistant Professor at Harvard Medical School, with a focus on computational drug discovery and target validation. He holds a PhD in Biochemistry from Canada’s Western University.